IL1B and atherosclerosis: In a large clinical trial, the Canakinumab Anti-inflammatory Thrombosis Outcome Study (CANTOS), anti-inflammatory therapy against atherosclerosis was found to be effective, and IL-1β played an important role in atherosclerotic plaque generation [20].